Clinical Trials
Pasritamig vs. best supportive care in metastatic castrate resistant prostate cancer
Disease Type: Prostate
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T cell redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer.
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville